Zymeworks Inc. (ZYME) stock
ZYMENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 5/30667% above fair value
$26.04+0.20 (+0.77%)
Close on Nov 18, 2026Market cap $1.85BP/E –Yield –
Zymeworks net income
Net income is the profit left for shareholders after every expense, interest and tax.
Zymeworks's net income for the twelve months ending Jun 30, 2026 was -$149.99M. For fiscal 2025 it was -$81.13M. The highest annual figure on record is $124.34M in fiscal 2022.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$81.13M | – |
| FY2024 | Dec 31, 2024 | -$122.70M | – |
| FY2023 | Dec 31, 2023 | -$118.67M | -195.4% |
| FY2022 | Dec 31, 2022 | $124.34M | – |
| FY2021 | Dec 31, 2021 | -$211.84M | – |
| FY2020 | Dec 31, 2020 | -$180.55M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$45.02M | -2043.0% |
| Q1 FY2026 | Mar 31, 2026 | -$44.16M | – |
| Q4 FY2025 | Dec 31, 2025 | -$41.21M | – |
| Q3 FY2025 | Sep 30, 2025 | -$19.60M | – |
| Q2 FY2025 | Jun 30, 2025 | $2.32M | – |
| Q1 FY2025 | Mar 31, 2025 | -$22.64M | – |
| Q4 FY2024 | Dec 31, 2024 | -$23.51M | – |
| Q3 FY2024 | Sep 30, 2024 | -$29.85M | – |
| Q2 FY2024 | Jun 30, 2024 | -$37.69M | – |
| Q1 FY2024 | Mar 31, 2024 | -$31.65M | – |
| Q4 FY2023 | Dec 31, 2023 | -$14.48M | -104.7% |
| Q3 FY2023 | Sep 30, 2023 | -$28.69M | – |
| Q2 FY2023 | Jun 30, 2023 | -$51.15M | – |
| Q1 FY2023 | Mar 31, 2023 | -$24.35M | – |
| Q4 FY2022 | Dec 31, 2022 | $309.43M | – |
| Q3 FY2022 | Sep 30, 2022 | -$47.85M | – |
| Q2 FY2022 | Jun 30, 2022 | -$64.62M | – |
| Q1 FY2022 | Mar 31, 2022 | -$72.63M | – |
| Q4 FY2021 | Dec 31, 2021 | -$39.15M | – |
| Q3 FY2021 | Sep 30, 2021 | -$60.58M | – |
| Q2 FY2021 | Jun 30, 2021 | -$67.52M | – |
| Q1 FY2021 | Mar 31, 2021 | -$44.59M | – |
See a number that looks wrong?